Actelion Ltd. Announces U.S. Commercial Availability of OPSUMIT® (macitentan) as of November 4
Published: Nov 04, 2013
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Actelion (SIX: ATLN) today announced the commercial availability of OPSUMIT® (macitentan) 10mg, an oral, dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. PAH is a chronic, life-threatening disorder that can severely compromise the function of the lungs and heart. The U.S. Food and Drug Administration (FDA) approved OPSUMIT on October 18, 2013.
Help employers find you! Check out all the jobs and post your resume.